FDA Approves Merck's KEYTRUDA + Padcev Regimens For Muscle-Invasive Bladder Cancer

Source Summary

KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK) announced that the U.S. Food and Drug Administration approved KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa...